Mind the Gap: Patients with Mental Disorders Face Significant Disparities in Diabetes Monitoring and Modern Therapies
Posted inDiabetes & Endocrinology news Psychiatry

Mind the Gap: Patients with Mental Disorders Face Significant Disparities in Diabetes Monitoring and Modern Therapies

A massive systematic review of 5.5 million patients reveals that those with mental disorders receive significantly lower quality diabetes care, including less frequent monitoring and a 74% lower likelihood of being prescribed GLP-1 receptor agonists compared to those without psychiatric conditions.
Rare but Severe: Characterizing Immune Checkpoint Inhibitor-Induced Diabetes in 13,966 Trial Participants
Posted inDiabetes & Endocrinology news Oncology

Rare but Severe: Characterizing Immune Checkpoint Inhibitor-Induced Diabetes in 13,966 Trial Participants

A large-scale NCI study reveals that while immune checkpoint inhibitor-induced diabetes is rare (0.52%), it is highly morbid, often requiring hospitalization or ICU care. Risk varies significantly by treatment regimen, with combination immunotherapy increasing risk and concurrent chemotherapy appearing protective.
Diabetes and Dementia Biomarkers: Less Alzheimer’s Pathology but More Non‑AD Neurodegeneration in Cognitively Normal Adults
Posted inDiabetes & Endocrinology Neurology news

Diabetes and Dementia Biomarkers: Less Alzheimer’s Pathology but More Non‑AD Neurodegeneration in Cognitively Normal Adults

A pan‑European analysis (n=5,550) found diabetes was associated with lower odds of amyloid and p‑tau pathology in cognitively impaired patients, but with markers of neurodegeneration (total tau, medial temporal atrophy) in cognitively normal individuals without amyloid — suggesting non‑AD pathways link diabetes to cognitive decline.
Evaluating AI-Led vs Human-Led Lifestyle Interventions in Prediabetes: Evidence from a Randomized Clinical Trial of the Diabetes Prevention Program
Posted inAI Clinical Updates Diabetes & Endocrinology news

Evaluating AI-Led vs Human-Led Lifestyle Interventions in Prediabetes: Evidence from a Randomized Clinical Trial of the Diabetes Prevention Program

This review examines the first phase 3 randomized trial demonstrating that an AI-powered Diabetes Prevention Program lifestyle intervention is noninferior to human coaching in improving weight loss, HbA1c, and physical activity among adults with prediabetes and overweight or obesity.